Tuberculosis - Strategies towards anti-infectives for a chronic disease

Drug Discovery Today: Therapeutic Strategies

Volumn 1, Issue 4, 2004, Pages 491-496

  Barry III, Clifton E ^a   Duncan, Ken ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ACETOLACTATE SYNTHASE INHIBITOR; ADENOSINE DERIVATIVE; ANTIINFECTIVE AGENT; ENZYME INHIBITOR; ETHAMBUTOL; MOXIFLOXACIN; NATURAL PRODUCT; NITROIMIDAZOLE; OXAZOLIDINONE DERIVATIVE; PEPTIDE DEFORMYLASE INHIBITOR; PYRROLE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOXALINE DERIVATIVE; RIFALAZIL; RIFAMPICIN DERIVATIVE; RIFAPENTINE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CHRONIC DISEASE; DRUG DESIGN; DRUG HALF LIFE; HUMAN; MORTALITY; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; TUBERCULOSIS; TUBERCULOSIS CONTROL;

EID: 4644318519     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2004.10.007     Document Type: Article

References (40)

1. E.L. Corbett et al. The growing burden of tuberculosis: Global trends and interactions with the HIV epidemic Arch. Intern. Med. 163 2003 1009-1021
2. M.A. Espinal The global situation of MDR-TB Tuberculosis 83 2003 44-51
3. Global Alliance for TB Drug Development Tuberculosis. Scientific blueprint for tuberculosis drug development Tuberculosis 81 Suppl. 1 2001 1-52
4. K. Duncan C.E. Barry III Prospects for new antitubercular drugs Curr. Opin. Microbiol. 7 2004 460-465
5. D. Benator et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: A randomised clinical trial Lancet 360 2002 528-534
6. N.N. Bock et al. A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1200 mg plus isoniazid in the continuation phase of tuberculosis treatment Am. J. Respir. Crit. Care Med. 165 2002 1526-1530
7. D.M. Rothstein et al. Development potential of rifalazil Exp. Opin. Invest. Drugs 12 2003 255-271
8. R.E. Lee et al. Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis preclinical candidates J. Comb. Chem. 5 2003 172-187
9. T. Aboul-Fadl K. Hassanin Tetrahydro-2H-1,3,5-thiadiazine-5-(4-pyridylcarboxamide)-2-thione derivatives as prodrugs for isoniazid; synthesis, investigations and in vitro antituberculous activity Pharmazie 54 1999 244-247
10. M.J. Hearn M.H. Cynamon Design and synthesis of antituberculars: preparation and evaluation against Mycobacterium tuberculosis of an isoniazid Schiff base J. Antimicrob. Chemother. 53 2004 185-191
11. E.L. Nuermberger et al. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis Am. J. Respir. Crit. Care Med. 169 2004 421-426
12. R.D. Gosling et al. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis Am. J. Respir. Crit. Care Med. 168 2003 1342-1345
13. M.W.R. Pletz et al. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: A prospective, randomized study Antimicrob. Agents Chemother. 48 2004 780-782
14. H.I. Boshoff et al. The transcriptional responses of M. tuberculosis to inhibitors of metabolism: Novel insights into drug mechanisms of action J. Biol. Chem. 279 2004 40174-40184
15. J.C. Betts et al. Signature gene expression profiles discriminate between isoniazid-, thiolactomycin- and triclosan-treated Mycobacterium tuberculosis Antimicrob. Agents Chemother. 47 2003 2903-2913
16. S. Khasnobis et al. Emerging therapeutic targets in tuberculosis: post-genomic era Exp. Opin. Ther. Targets 6 2002 21-40
17. C.M. Sassetti et al. Genes required for mycobacterial growth defined by high density mutagenesis Mol. Microbiol. 48 2003 77-84
18. C.M. Sassetti E.J. Rubin Genetic requirements for mycobacterial survival during infection Proc. Natl. Acad. Sci. USA 100 2003 12989-12994
19. J.D. McKinney et al. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase Nature 406 2000 735-738
20. T.P. Primm et al. The stringent response of Mycobacterium tuberculosis is required for long-term survival J. Bacteriol. 182 2000 4889-4898
21. H.I. Boshoff et al. DnaE2 polymerase contributes to in vivo survival and the emergence of drug resistance in Mycobacterium tuberculosis Cell 113 2003 183-193
22. M.S. Glickman et al. A novel mycolic acid cyclopropane synthetase is required for cording, persistence, and virulence of Mycobacterium tuberculosis Mol. Cell 5 2000 717-727
23. M.I. Voskuil et al. Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program J. Exp. Med. 198 2003 705-713
24. L.G. Wayne C.D. Sohaskey Nonreplicating persistence of Mycobacterium tuberculosis Annu. Rev. Microbiol. 55 2001 139-163
25. J.C. Betts et al. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling Mol. Microbiol. 43 2002 717-731
26. Y. Hu et al. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis Antimicrob. Agents Chemother. 47 2003 653-657
27. H. Engelberg-Kulka et al. Bacterial programmed cell death systems as targets for antibiotics Trends Microbiol. 12 2004 66-71
28. J. Timm et al. Differential expression of iron-, carbon-, and oxygen-responsive mycobacterial genes in the lungs of chronically infected mice and tuberculosis patients Proc. Natl. Acad. Sci. USA 100 2003 14321-14326
29. G. Fenhalls et al. In situ detection of Mycobacterium tuberculosis transcripts in human lung granulomas reveals differential gene expression in necrotic lesions Infect. Immun. 70 2002 6330-6338
30. S.V. Capuano et al. Experimental Mycobacterium tuberculosis infection of cynomolgus Macaques closely resembles the various manifestations of human M. tuberculosis infection Infect. Immun. 71 2003 5831-5844
31. A.L. Okunade et al. Natural antimycobacterial metabolites: Current status Phytochemistry 65 2004 1017-1032
32. A.K. Pathak et al. Antimycobacterial agents 1. Thio analogues of purine J. Med. Chem. 47 2004 273-276
33. J.N. Peng et al. Manadomanzamines A and B: A novel alkaloid ring system with potent activity against mycobacteria and HIV-1 J. Am. Chem. Soc. 125 2003 13382-13386
34. A. Jaso et al. Synthesis of new 2-acetyl and 2-benzoyl quinoxaline 1, 4-di-N-oxide derivatives as anti-Mycobacterium tuberculosis agents Eur. J. Med. Chem. 38 2003 791-800
35. M. Biava et al. Importance of the thiomorpholine introduction in new pyrrole derivatives as antimycobacterial agents analogues of BM 212 Bioorg. Med. Chem. 11 2003 515-520
36. C.K. Stover et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis Nature 405 2000 962-966
37. M.H. Cynamon et al. BB-3497, a peptide deformylase inhibitor, is active against Mycobacterium tuberculosis J. Antimicrob. Chemother. 53 2004 403-405
38. Y. Zohar et al. Acetohydroxyacid synthase from Mycobacterium avium and its inhibition by sulfonylureas and imidazolinones Biochim. Biophys. Acta 1649 2003 97-105
39. M.S. Scherman et al. Drug targeting Mycobacterium tuberculosis cell wall synthesis: Development of a microtiter plate-based screen for UDP-galactopyranose mutase and identification of an inhibitor from a uridine-based library Antimicrob. Agents Chemother. 47 2003 378-382
40. E.W. Barrow et al. Antimycobacterial activity of 2-methyl-adenosine J. Antimicrob. Chemother. 52 2003 801-808